Adaptimmune Therapeutics PLC — Director's Dealing 2017

Jul 3, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2017-07-03

Reporting Person: Kerr Giles Francis Bertram (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-03	Option to purchase Ordinary Shares	$0.75	A	144000	Acquired	2027-07-03	Ordinary Shares (144000)	Direct

Footnotes

F1: The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.